StockData
Certara, Inc. logo

Certara, Inc. (CERT) stock

CERTNasdaqServices-Prepackaged SoftwareFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% below fair value
$11.90+0.17 (+1.45%)

Close on Nov 12, 2026Market cap $1.82BP/E –Yield –

Earnings

Certara's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$94.90M
-9.3% on a year earlier
Adjusted diluted earnings per share, Q3 FY2026
$0.09
$0.14 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Certara's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$94.90M-9.3%-$0.02$0.09Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026before the open$93.30M-10.8%-$0.04$0.08Release
Q1 FY2026ended Mar 31, 2026May 11, 2026before the open$106.90M+0.8%-$0.06–Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$103.60M+3.2%-$0.04$0.09Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$104.60M+10.3%$0.01$0.14Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025during market hours$104.60M+12.1%-$0.01$0.07Release
Q1 FY2025ended Mar 31, 2025May 5, 2025during market hours$106.00M+9.6%$0.03$0.14Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025during market hours$100.40M+14.1%$0.04$0.15Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours$94.80M+10.7%-$0.01$0.13Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours$93.30M+3.1%-$0.08$0.07Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$96.70M+7.1%-$0.03$0.10Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Certara's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Full year 2026 revenueFY2026$395.00M – $405.00M–NewMay 11, 2026
Growth excluding the Regulatory and Medical Writing BusinessFY20260% – +4%0% – +4%ReaffirmedMay 11, 2026
revenuenon-GAAPFY2026$367.00M – $382.00M–NewAug 4, 2026
revenue growthFY2026+2% – +3%–NewNov 5, 2026
Revenue growth for Continuing Operations, excluding the Regulatory and Medical Writing businessnon-GAAPFY20260% – +4%–NewAug 4, 2026
Full year 2026 Adjusted EBITDA marginnon-GAAPFY202630% – 32%30% – 32%ReaffirmedMay 11, 2026
adjusted EBITDA marginnon-GAAPFY202629% – 31%–NewNov 5, 2026
adjusted diluted earnings per sharenon-GAAPFY2026$0.31 – $0.34–NewNov 5, 2026
adjusted diluted earnings per share for Continuing Operations, excluding the Regulatory and Medical Writing businessnon-GAAPFY2026$0.31 – $0.36$0.35 – $0.41LoweredAug 4, 2026
adjusted EBITDA margin for Continuing Operations, excluding the Regulatory and Medical writing businessnon-GAAPFY202629% – 31%–NewAug 4, 2026
effective tax rateFY202625% – 30%–NewNov 5, 2026
Fully diluted sharesFY2026155 – 157157 – 159LoweredAug 4, 2026
Fully diluted weighted average shares outstandingFY2026155 – 157–NewNov 5, 2026

Guidance vs results

The last range Certara gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025adjusted diluted earnings per share$0.45 – $0.47$0.44Σ4QBelow range
FY2025Revenue$415.00M – $420.00M$418.80MΣ4QWithin range

Guidance history

Every forecast Certara put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026adjusted EBITDA marginFY202629% – 31%New
Nov 5, 2026adjusted diluted earnings per shareFY2026$0.31 – $0.34New
Nov 5, 2026Fully diluted weighted average shares outstandingFY2026155 – 157New
Nov 5, 2026effective tax rateFY202625% – 30%New
Nov 5, 2026revenue growthFY2026+2% – +3%New
Aug 4, 2026adjusted diluted earnings per share for Continuing Operations, excluding the Regulatory and Medical Writing businessFY2026$0.31 – $0.36Lowered
Aug 4, 2026Fully diluted sharesFY2026155 – 157Lowered
Aug 4, 2026adjusted EBITDA margin for Continuing Operations, excluding the Regulatory and Medical writing businessFY202629% – 31%New
Aug 4, 2026Revenue growth for Continuing Operations, excluding the Regulatory and Medical Writing businessFY20260% – +4%New
Aug 4, 2026revenueFY2026$367.00M – $382.00MNew
May 11, 2026Full year adjusted diluted earnings per shareFY2026$0.35 – $0.41Lowered
May 11, 2026Full year 2026 Adjusted EBITDA marginFY202630% – 32%Reaffirmed
May 11, 2026Fully diluted sharesFY2026157 – 159Lowered
May 11, 2026Growth excluding the Regulatory and Medical Writing BusinessFY20260% – +4%Reaffirmed
May 11, 2026Full year 2026 revenueFY2026$395.00M – $405.00MNew
Feb 26, 2026adjusted diluted earnings per shareFY2026$0.44 – $0.48New
Feb 26, 2026adjusted EBITDA marginFY202630% – 32%New
Feb 26, 2026Fully diluted sharesFY2026160 – 162New
Feb 26, 2026revenueFY20260% – +4%New
Nov 6, 2025adjusted diluted earnings per shareFY2025$0.45 – $0.47New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Certara filed with the SEC as exhibits to Form 8-K or 6-K

  1. Certara Reports Third Quarter 2026 Financial Results
    Results
  2. Certara Reports Second Quarter 2026 Financial Results
    Results
  3. Certara Reports First Quarter 2026 Financial Results
    Results
  4. Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
    Results
  5. Certara Reports Third Quarter 2025 Financial Results
    Results
  6. Certara Reports Second Quarter 2025 Financial Results
    Results
  7. Certara Reports First Quarter 2025 Financial Results
    Results
  8. Certara Reports Preliminary First Quarter 2025 Financial Results;
    Results
  9. Certara Reports Fourth Quarter 2024 Financial Results
    Results
  10. Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
    Results
  11. Certara Reports Third Quarter 2024 Financial Results
    Results
  12. Certara Reports Second Quarter 2024 Financial Results
    Results
  13. Certara to Acquire Chemaxon to Strengthen Drug
    Update
  14. Certara Reports First Quarter 2024 Financial Results
    Results
  15. Certara Reports Fourth Quarter 2023 Financial Results
    Results

See a number that looks wrong?